Basic Information
TALZENNA CAPSULE 1MG
CAPSULE
Regulatory Information
SIN15945P
May 22, 2020
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
Company Information
Active Ingredients
Talazoparib tosylate eqv Talazoparib
Strength: 1 mg
Detailed Information
Contraindications
**4.3. Contraindications** None.
Indication Information
**4.1. Therapeutic indications** TALZENNA is indicated for the treatment of adult patients with germline breast cancer susceptibility gene (BRCA)-mutated human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have previously been treated with chemotherapy. These patients could have received chemotherapy in the neoadjuvant, adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments.